About pralatrexate
Antifolate chemotherapy medicine
Used for
- Treats relapsed or refractory peripheral T-cell lymphoma.
Usual adult dose
30 mg/m² intravenously once weekly for six weeks of a seven-week cycle; dose may be adjusted for toxicity.
Common side effects
- Mouth sores or inflammation
- Low blood cell counts
- Nausea and vomiting
- Fatigue
Important warnings
- Can cause severe mouth sores and serious infections or bleeding from low blood counts.
- Folic acid and vitamin B12 supplementation are required during treatment.
- Avoid during pregnancy; may harm an unborn baby.
- Use by specialist oncology teams with blood-count and toxicity monitoring.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment; effective contraception is recommended.
Breastfeeding
Breastfeeding is not recommended during treatment and for one week after the last dose.
Interactions
- Probenecid may increase pralatrexate exposure.
- Some NSAIDs, such as ibuprofen, may increase toxicity.
- Trimethoprim-sulfamethoxazole may increase antifolate-related toxicity.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.